4:55 PM
 | 
Nov 16, 2012
 |  BC Extra  |  Clinical News

Lyrica CR misses Phase III epilepsy endpoint

Pfizer Inc. (NYSE:PFE) said once-daily 165 and 330 mg Lyrica CR pregabalin controlled-release as adjunctive treatment of partial onset seizures in adults with epilepsy each missed the primary endpoint in a Phase III trial. Specifically, both doses missed the primary endpoint of reducing the log-transformed 28-day...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >